Weed Stock Price, News & Analysis

WEED Inc. (OTCQB: BUDZ) is a global cannabis and hemp bioresearch company based in the United States. According to the company’s public statements, WEED Inc. focuses on the development and application of cannabis-derived compounds for the treatment of human and animal diseases. The company is associated with the medicinal and botanical manufacturing industry and operates within the broader manufacturing sector.

WEED Inc. describes itself as a multi-national cannabis holding company with activities and subsidiaries in the USA, Israel and Australia, and past operations in Hong Kong and Colorado. Through WEED Australia Ltd., WEED Israel (Cannabis) Ltd., HEMP BioSciences Inc., and other entities, the company emphasizes research, product development and intellectual property around the Cannabaceae plant, including both high-THC and cannabidiol (CBD) compounds.

Business focus and bioresearch activities

Across its disclosures and news releases, WEED Inc. consistently states that its core focus is on medical cannabis and hemp bioresearch. The company highlights efforts to explore cannabis-derived compounds for human and animal health, including planned and ongoing work related to:

• Human clinical trials and product development in Israel and Australia, with an emphasis on women’s health and veterans’ ailments such as PTSD, using THC and cannabinoid studies.
• Developing both pharmaceutical and non-pharmaceutical categories of cannabis-based products.
• Educational tools for doctors, health practitioners and the public, often referenced through its Australian non-profit arm, The Cannabis Institute of Australia.

WEED Inc. notes that it believes many discoveries in cannabis and hemp remain to be found and frequently links long-term success to research into cannabinoid combinations and the “entourage effect.”

Landrace genetics and seedbank

A distinctive aspect of WEED Inc.’s profile is its emphasis on rare landrace and heritage cannabis genetics. The company reports that it has built an extensive seedbank over decades, including strains such as Original Panama Red, Acapulco Gold, Red Bud Colombian, Santa Marta Gold, African Ebony, Jamaican, Thai (Thai Sticks) and Andalusian Nepalese. WEED Inc. and its partners describe these as F-1 grade landrace and heirloom strains, with a seedbank of over 200 rare and authenticated strains of sativa, indica and hybrid crosses.

Through the acquisition of Hempirical Genetics LLC, WEED Inc. states that it added over 250 proprietary cannabis and hemp strains, including more than 30 CBD and CBG strains. The company positions this genetics portfolio as a foundation for clinical trials, product development and future consumer packaged goods using its landrace strains when regulations allow.

Subsidiaries and geographic footprint

WEED Inc. highlights several key subsidiaries and related entities in its public communications:

• WEED Australia Ltd. – A majority-owned subsidiary (described as a public company reporting under Australian Securities and Investment Commission rules) based in Queensland on the Gold Coast. WEED Australia is associated with medical cannabis research, clinical trials and product development for the Australian market, and has completed multiple years of audited financial statements under ASIC rules.
• The Cannabis Institute of Australia (C.I.A.) – Described as a non-profit arm tied to WEED Australia, focused on cannabis and hemp research, including clinical trials for pharmaceutical and non-pharmaceutical products and services.
• WEED Israel (Cannabis) Ltd. – Based outside Jerusalem, this entity is described as poised to build out global brands in pharmaceutical and non-pharmaceutical categories, with a focus on clinical trials using THC and cannabinoids for women’s health and veterans’ ailments.
• HEMP BioSciences Inc. – A wholly owned Arizona corporation that holds industrial hemp licenses in Arizona. WEED Inc. reports that HEMP BioSciences has been issued licenses for growing, nursery, harvester, transporter and processor activities under Arizona’s industrial hemp framework, and that it is working toward a cGMP-certified kitchen for manufacturing hemp-derived consumer packaged goods.
• WEED Hong Kong Ltd. – Previously formed to handle international intellectual property but later deregistered and dissolved for cost-cutting reasons, with WEED Inc. stating that it retains IP, trademarks and registered marks in the USA.

WEED Inc. also notes that it exited the Colorado cannabis marketplace through the sale of a research campus and headquarters, redirecting resources toward Arizona and other strategic areas.

Consumer packaged goods and hemp operations

In multiple news releases, WEED Inc. states that it intends to expand into consumer packaged goods (CPG) using its rare landrace strains. Through HEMP BioSciences, the company describes plans for hemp-derived products such as CBD gummies, oils, creams, tinctures and balms, and references low-THC and CBD products under industrial hemp regulations. HEMP BioSciences communications describe hemp cultivation and processing under supercritical CO2 extraction, with an emphasis on phytochemical properties and compliance with THC limits for industrial hemp.

Statements from HEMP BioSciences’ management highlight goals to produce cannabidiol products that are safe, effective and affordable, using proprietary hemp strains and quality control standards. The company also references the potential of cannabinoids such as CBD, CBG and CBN, while emphasizing that investors should review risk factors and legal disclosures due to the complex regulatory environment for cannabis in the United States.

Intellectual property, trademarks and branding

WEED Inc. places significant emphasis on intellectual property (IP) and branding. The company reports that it:

• Holds registered trademarks for WEED in the USA and Canada for certain goods such as stickers, postcards, posters and related printed materials.
• Has obtained a registered mark for Panama Red in the USA and Canada for categories including downloadable and non-downloadable software for social networking education in the field of tobacco, printed materials, and entertainment services such as music festivals and concerts.
• Holds a service mark allowance for “WEED Rules!” covering apparel (hats, T-shirts and other clothing) and promotional services related to consumer information and news in the field of marijuana and cannabis and medicinal and therapeutic cannabis-infused products.
• Is pursuing or has pursued trademark applications for WEED, PANAMA RED and ACAPULCO GOLD in connection with goods and services that include smoking accessories, rolling papers, grinders, tobacco pipes, nutritional supplements for pets, cosmetics, cleaning preparations, paper goods, printed matter, natural agricultural products, social networking software, and organizing concerts and festivals.

These trademark and IP efforts are described by the company as part of a broader plan to expand its brands into multiple categories beyond core cannabis-derived healthcare and adult-use products.

AI, crypto, blockchain and tokenization initiatives

In a later news release, WEED Inc. announces that it intends to enter the AI/crypto/blockchain arena through a strategic partnership with Remergify Inc., described as a boutique advisory firm focused on blockchain, NFTs and strategic partnerships. Under this partnership, WEED Inc. and Remergify plan to design, develop, program, deploy and coordinate the launch of WEEDCoin and BUDZCoin, which are described as stablecoin-oriented tokens aimed at addressing banking and cash challenges in the highly regulated cannabis and hemp marketplace.

The company and Remergify outline goals that include:

• Creating a “Stablecoin Treasury” using WEEDCoin (B2C) and BUDZCoin (B2B) for businesses and consumers.
• Developing blockchain solutions and NFT technology to tokenize WEED Inc.’s cannabis genetics, including its OG seedbank, to create provenance, breeding rights and potential royalty streams for growers, dispensaries and partners.
• Exploring AI tools focused on improving aspects of the cannabis industry.

These initiatives are described as intended to help transform WEED Inc.’s uncapitalized assets, such as its seedbank and IP, into revenue-generating operations, subject to regulatory requirements and market conditions.

Regulatory environment and risk disclosures

In repeated cautionary statements, WEED Inc. emphasizes that cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under U.S. federal law to cultivate, distribute or possess cannabis, even though it is legal in certain states. The company notes that financial transactions involving proceeds from cannabis-related business activities may be subject to U.S. federal money laundering laws.

WEED Inc. advises prospective investors to carefully read risk factors and disclosures in its offering materials and SEC filings, and states that its news releases contain forward-looking information that is not a guarantee of future performance. The company frequently notes that actual results may differ materially from forward-looking statements and that it does not undertake to update such information except as required by applicable securities laws.

Public company status and SEC reporting

WEED Inc. trades under the symbol BUDZ on the OTCQB market. In a Form 12b-25 (Notification of Late Filing), the company reported that its Quarterly Report on Form 10-Q for the period ended September 30, 2025, could not be filed within the prescribed time without unreasonable effort or expense, and indicated that it expected to file within the extension period allowed under SEC rules. The filing also confirms that all other required periodic reports over the preceding 12 months had been filed, and that no significant change in results of operations from the corresponding prior-year period was anticipated for that quarter.

Legal and geographic notes

WEED Inc. repeatedly underscores that its operations are affected by evolving cannabis regulations in the United States and internationally. The company references:

• Australian regulatory developments, including over-the-counter CBD medicines in pharmacies and the role of Australian agencies such as ASIC, the Office of Drug Control and the Therapeutic Goods Administration.
• Clinical trial and research ambitions in Israel and Australia.
• Past attendance at industry conferences such as the United in Compassion Australian Medicinal Cannabis Symposium.

Across its communications, WEED Inc. presents itself as focused on cannabis and hemp bioresearch, landrace genetics, intellectual property, hemp-derived products and emerging blockchain and AI initiatives, while highlighting the legal complexities and risks inherent in the cannabis industry.